Rebecka Hellsten

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. doi request reprint Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3
    Rebecka Hellsten
    Division of Urological Cancers, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Prostate 68:269-80. 2008
  2. pmc Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells
    Rebecka Hellsten
    Division of Urological Cancers, Department of Clinical Sciences, Lund University, Malmo, Sweden
    PLoS ONE 6:e22118. 2011
  3. doi request reprint Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
    Zilma Escobar
    Center for Analysis and Synthesis, Lund University, SE 221 00 Lund, Sweden
    J Med Chem 59:4551-62. 2016
  4. doi request reprint Expression of STAT3 in Prostate Cancer Metastases
    Nicholas Don-Doncow
    Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmo, Sweden
    Eur Urol . 2016
  5. pmc Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells
    Nicholas Don-Doncow
    From the Division of Urological Cancers, Lund University, SE 205 02 Malmo, Sweden
    J Biol Chem 289:15969-78. 2014
  6. doi request reprint The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer
    Giacomo Canesin
    Department of Translational Medicine, Division of Cell and Experimental Pathology, Lund University, Sweden Department of Translational Medicine, Division of Urological Cancers, Skåne University Hospital Malmö, Lund University, Sweden
    Eur Urol 69:400-4. 2016
  7. ncbi request reprint A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue
    Camilla Valtonen-Andre
    Lund University, Division of Clinical Chemistry, Department of Laboratory Medicine, University Hospital MAS, S 205 02 Malmo, Sweden
    Biol Chem 388:289-95. 2007

Collaborators

  • Anders Bjartell
  • Hans Lilja
  • Nishtman Dizeyi
  • Colm Morrissey
  • Nicholas Don-Doncow
  • Giacomo Canesin
  • Olov Sterner
  • Zilma Escobar
  • Susan Evans-Axelsson
  • Agnieszka Krzyzanowska
  • Camilla Valtonen-Andre
  • Tommy Andersson
  • Martin H Johansson
  • Ilsa Coleman
  • Roy Ehrnstrom
  • Peter S Nelson
  • Felicia Marginean
  • Eduardo Munoz
  • Martin Johansson
  • Victor Garcia
  • Sven Kjellström
  • Pirkko Härkönen
  • Ake Lundwall

Detail Information

Publications7

  1. doi request reprint Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3
    Rebecka Hellsten
    Division of Urological Cancers, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Prostate 68:269-80. 2008
    ..In this study we investigated the in vitro and in vivo effects of the fungal metabolite galiellalactone, a direct inhibitor of Stat3, on PCa cells...
  2. pmc Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells
    Rebecka Hellsten
    Division of Urological Cancers, Department of Clinical Sciences, Lund University, Malmo, Sweden
    PLoS ONE 6:e22118. 2011
    ....
  3. doi request reprint Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
    Zilma Escobar
    Center for Analysis and Synthesis, Lund University, SE 221 00 Lund, Sweden
    J Med Chem 59:4551-62. 2016
    ..The favorable druglike properties and safety profile of 6 warrant further studies of 6 for the treatment of castration-resistant prostate cancer. ..
  4. doi request reprint Expression of STAT3 in Prostate Cancer Metastases
    Nicholas Don-Doncow
    Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmo, Sweden
    Eur Urol . 2016
    ..Our study strongly supports the suggested view of targeting STAT3 as a therapeutic option in patients with metastatic CRPC...
  5. pmc Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells
    Nicholas Don-Doncow
    From the Division of Urological Cancers, Lund University, SE 205 02 Malmo, Sweden
    J Biol Chem 289:15969-78. 2014
    ..This further validates galiellalactone as a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer. ..
  6. doi request reprint The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer
    Giacomo Canesin
    Department of Translational Medicine, Division of Cell and Experimental Pathology, Lund University, Sweden Department of Translational Medicine, Division of Urological Cancers, Skåne University Hospital Malmö, Lund University, Sweden
    Eur Urol 69:400-4. 2016
    ..Our results showed that tumor growth and early metastatic dissemination of PCa can be significantly reduced by GL, indicating its potential use as a therapeutic compound in advanced metastatic PCa...
  7. ncbi request reprint A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue
    Camilla Valtonen-Andre
    Lund University, Division of Clinical Chemistry, Department of Laboratory Medicine, University Hospital MAS, S 205 02 Malmo, Sweden
    Biol Chem 388:289-95. 2007
    ..Studies on human prostate cancer specimens showed immunohistochemical staining of both tumor and benign glandular cells. Our results suggest that PSMP is an important protein with significance in prostate cancer...